SNOA Sonoma Pharmaceuticals, Inc.
Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 1367083 · Fiscal year ends 03/31
Financial factors as of 2026-09-30 (2027Q2), TTM = sum of the last four quarters
Growth
TTM revenue YoY38.7%
TTM net income YoY48.4%
TTM EPS YoY55.2%
Revenue 3-yr CAGR24.7%
Net income 3-yr CAGR—
Margins
Gross margin39.2%
Operating margin-3.3%
Net margin-7.6%
FCF margin-11.9%
EBITDA margin-2.8%
Returns
ROE-34.5%
ROA-11.6%
ROIC (approx.)-44.6%
Asset turnover1.52x
Leverage & solvency
Liabilities / assets61.3%
Debt / equity0.00x
Current ratio3.48x
Interest coverage—
Cash quality & payout
Operating cash flow / net income1.49x
Accruals ratio5.6%
Payout ratio—
Capex / revenue0.5%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20262026-03-31 | FY20252025-03-31 | FY20242024-03-31 | FY20232023-03-31 | FY20222022-03-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $19.53M | $14.29M | $12.73M | $13.27M | $12.63M |
| Cost of revenue | $12.11M | $8.82M | $7.99M | $8.79M | $8.63M |
| Gross profit | $7.42M | $5.46M | $4.75M | $4.48M | $3.99M |
| R&D expense | $2.27M | $1.81M | $1.87M | $207,000 | $125,000 |
| SG&A expense | $7.61M | $7.36M | $7.58M | $8.84M | $9.76M |
| Operating income | -$2.46M | -$3.71M | -$4.70M | -$4.57M | -$5.89M |
| Pretax income | -$3.42M | -$2.91M | -$5.03M | -$5.18M | -$5.42M |
| Income tax | -$244,000 | $550,000 | -$196,000 | -$33,000 | -$332,000 |
| Net income | -$3.17M | -$3.46M | -$4.83M | -$5.15M | -$5.09M |
| EBITDA | -$2.32M | -$3.57M | -$4.53M | -$4.45M | -$5.70M |
| EPS (basic) | -1.89 | -2.79 | -10.63 | -1.52 | -1.92 |
| EPS (diluted) | -1.89 | -2.79 | -10.63 | -1.52 | -1.92 |
| Weighted avg. shares (diluted) | 1.68M | 1.24M | 455,000 | 3.39M | 2,653 |
| Banking | |||||
| Net interest income | — | — | — | $16,000 | -$10,000 |
| Balance sheet | |||||
| Cash & equivalents | $2.40M | $5.37M | $3.13M | $3.82M | $7.40M |
| Receivables | $2.53M | $2.23M | $2.90M | $2.57M | $2.41M |
| Inventory | $3.65M | $2.92M | $2.72M | $2.86M | $2.66M |
| Current assets | $12.10M | $12.65M | $12.55M | $13.80M | $16.43M |
| PP&E, net | $310,000 | $225,000 | $365,000 | $488,000 | $320,000 |
| Total assets | $13.96M | $13.69M | $14.74M | $16.23M | $18.84M |
| Current liabilities | $4.83M | $4.10M | $3.72M | $3.72M | $5.82M |
| Short-term debt | $222,000 | $220,000 | $323,000 | $431,000 | — |
| Long-term debt | — | — | — | — | $0 |
| Total debt | — | — | — | — | $0 |
| Total liabilities | $10.87M | $9.28M | $8.60M | $8.25M | $10.15M |
| Shareholders' equity | $3.10M | $4.41M | $6.14M | $7.98M | $8.70M |
| Net debt | — | — | — | — | -$7.40M |
| Shares outstanding | 1.80M | 1.63M | 780,371 | 4.93M | 3.10M |
| Cash flow statement | |||||
| Operating cash flow | -$3.93M | -$88,000 | -$2.40M | -$6.15M | -$4.25M |
| Capital expenditure | $192,000 | $80,000 | $2,000 | $269,000 | $137,000 |
| Free cash flow | -$4.12M | -$168,000 | -$2.40M | -$6.42M | -$4.38M |
| Investing cash flow | -$192,000 | -$80,000 | -$2,000 | -$258,000 | -$99,000 |
| Financing cash flow | $477,000 | $3.03M | $1.68M | $2.49M | $7.40M |
| Depreciation & amortization | $139,000 | $138,000 | $176,000 | $125,000 | $186,000 |
| Stock-based compensation | $255,000 | $224,000 | $516,000 | $669,000 | $382,000 |
Free plan shows the latest 5 periods; Pro shows all 16 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.